BCG-induced pneumonitis with lymphocytic pleurisy in the absence of elevated KL-6

BMC Pulm Med. 2014 Mar 5:14:35. doi: 10.1186/1471-2466-14-35.

Abstract

Background: Pneumonitis is a rare complication of bacillus Calmette-Guerin (BCG) immunotherapy seen in patients with urothelial cancer following the repeated administration of BCG. However, no case of BCG-induced pleurisy has been reported.

Case presentation: We here report the first case of pneumonitis with lymphocytic pleurisy following bacillus Calmette-Guerin (BCG) immunotherapy. Although marked T helper cell alveolitis was found by bronchoalveolar lavage and transbronchial biopsies, no acid-fast bacillus could be identified in recovered BALF or pleural effusion. The lymphocyte stimulation test of BCG was strongly positive. However, levels of serum and bronchoalveolar lavage fluid KL-6, a useful marker for hypersensitivity pneumonitis (HP), were within normal ranges.

Conclusion: We speculate that the pathogenesis of our case may be a hypersensitive reaction to the proteic component of BCG entering the lung and pleural space, which is different from the etiology of the common type of HP.

Publication types

  • Case Reports

MeSH terms

  • Adjuvants, Immunologic / adverse effects*
  • Adjuvants, Immunologic / therapeutic use
  • Aged, 80 and over
  • BCG Vaccine / adverse effects*
  • BCG Vaccine / therapeutic use
  • Carcinoma, Renal Cell / drug therapy
  • Female
  • Humans
  • Kidney Neoplasms / drug therapy
  • Lymphocytes*
  • Pleurisy / chemically induced*
  • Pleurisy / complications*
  • Pneumonia / chemically induced*
  • Pneumonia / complications*

Substances

  • Adjuvants, Immunologic
  • BCG Vaccine